Minimal Residual Disease MRD Analysis for T-ALL Test sale cost 3160 AED
Spinal Muscular Atrophy SMA Carrier Detection Test sale cost 2800 AED Spinal Muscular Atrophy SMA Carrier Detection Test Cost 3,600 د.إ Original price was: 3,600 د.إ.2,800 د.إCurrent price is: 2,800 د.إ.
Hemophilia A Common Mutation Screening Factor VIII Intron 22 Inversion Analysis Test sale cost 2400 AED Hemophilia A Common Mutation Screening Factor VIII Intron 22 Inversion Analysis Test Cost 3,200 د.إ Original price was: 3,200 د.إ.2,400 د.إCurrent price is: 2,400 د.إ.
Sale!

Minimal Residual Disease MRD Analysis for T-ALL Test Cost

Original price was: 3,510 د.إ.Current price is: 3,160 د.إ.

-10%

Minimal Residual Disease (MRD) analysis is a critical diagnostic tool used in the management of T-cell Acute Lymphoblastic Leukemia (T-ALL), a type of cancer that affects the white blood cells. This advanced testing method is designed to detect the smallest traces of cancer cells that remain in the patient’s body after treatment, which are often undetectable by traditional methods. The ability to accurately measure MRD helps oncologists assess the effectiveness of treatment, adjust therapy protocols accordingly, and predict patient outcomes with greater precision.

The MRD Analysis for T-ALL Test offered at DNA Labs UAE utilizes cutting-edge molecular and cytometric technologies to provide a highly sensitive assessment of disease status. This enables healthcare providers to make informed decisions regarding the need for additional treatment or intervention, thus optimizing patient care strategies and improving the chances of achieving long-term remission.

The cost of the MRD Analysis for T-ALL Test at DNA Labs UAE is 3160 AED. This investment in health allows patients and their families to access state-of-the-art diagnostic capabilities, contributing significantly to the personalized management of T-ALL and enhancing the likelihood of successful treatment outcomes.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

MINIMAL RESIDUAL DISEASE MRD ANALYSIS FOR T-ALL

Test Name: MINIMAL RESIDUAL DISEASE MRD ANALYSIS FOR T-ALL

Test Components: Surface and cytoplasmic: *CD3 *CD4 *CD5 *CD7 *CD8 *CD1a *CD16 *CD56 *CD34*TdT *CD99 *CD117 *CD38 *CD10 *CD45 *CD2/CD13/CD15/CD33

Price: 3160.0 AED

Sample Condition: 3 mL (1 mL min.) First pull Bone Marrow aspirate in 1 Green Top (Sodium Heparin) tube AND 4 mL (3 mL min.) whole blood in 1 Green Top (Sodium Heparin) tube. Ship immediately at 18-22°C. DO NOT REFRIGERATE OR FREEZE. It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history. All information should be given at the time of registration/before the sample is processed.

Report Delivery: Sample Daily by 9 am; Report 3 Working days

Method: Flow cytometry

Test type: Leukemia

Doctor: Hematologist, Oncologist

Test Department: FLOW CYTOMETRY

Pre Test Information: It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history.

Test Details

Minimal residual disease (MRD) analysis for T-cell acute lymphoblastic leukemia (T-ALL) is a diagnostic test used to detect small amounts of cancer cells that may remain in a patient’s body after treatment. T-ALL is a type of blood cancer that affects the lymphocytes, a type of white blood cell. After undergoing treatment, such as chemotherapy, radiation therapy, or stem cell transplant, some cancer cells may still be present in the body at very low levels. These residual cancer cells are called minimal residual disease.

MRD analysis involves the use of sensitive laboratory techniques to detect and quantify these residual cancer cells. The most commonly used method is flow cytometry, which can identify and count specific markers on the surface of cancer cells. Other techniques include polymerase chain reaction (PCR) and next-generation sequencing (NGS), which can detect specific genetic abnormalities associated with T-ALL.

The purpose of MRD analysis is to assess the effectiveness of treatment and to monitor disease progression or relapse. By detecting and quantifying minimal residual disease, doctors can determine if additional treatment is needed or if the disease is in remission. MRD analysis is typically performed at multiple time points during and after treatment, such as after induction therapy, consolidation therapy, and maintenance therapy.

The results are reported as a percentage of cancer cells detected in relation to the total number of cells analyzed. Overall, MRD analysis for T-ALL plays a crucial role in guiding treatment decisions and monitoring the response to therapy. It helps healthcare providers determine the appropriate course of action to achieve the best possible outcomes for patients with T-ALL.

Test Name MINIMAL RESIDUAL DISEASE MRD ANALYSIS FOR T-ALL Test
Components Surface and cytoplasmic:*CD3 *CD4 *CD5 *CD7 *CD8 *CD1a *CD16 *CD56 *CD34*TdT *CD99 *CD117 *CD38 *CD10 *CD45 *CD2/CD13/CD15/CD33
Price 3160.0 AED
Sample Condition 3 mL (1 mL min.) First pull Bone Marrow aspiratein 1 Green Top (Sodium Heparin) tube AND 4 mL (3 mL min.) whole blood in1 Green Top (Sodium Heparin )tube.\nShip immediately at 18-22?\u00f8C. DO NOT REFRIGERATE OR FREEZE. It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history. \nAll information should be given at the time of registration\/before the sample is processed.
Report Delivery Sample Daily by 9 am; Report 3 Working days
Method Flow cytometry.
Test type Leukemia
Doctor Hematologist, Oncologist
Test Department: FLOW CYTOMETRY
Pre Test Information It is mandatory to provide Date & Time of sampling, Previous immunophenotype report & Clinical history.
Test Details

Minimal residual disease (MRD) analysis for T-cell acute lymphoblastic leukemia (T-ALL) is a diagnostic test used to detect small amounts of cancer cells that may remain in a patient’s body after treatment.

T-ALL is a type of blood cancer that affects the lymphocytes, a type of white blood cell. After undergoing treatment, such as chemotherapy, radiation therapy, or stem cell transplant, some cancer cells may still be present in the body at very low levels. These residual cancer cells are called minimal residual disease.

MRD analysis involves the use of sensitive laboratory techniques to detect and quantify these residual cancer cells. The most commonly used method is flow cytometry, which can identify and count specific markers on the surface of cancer cells. Other techniques include polymerase chain reaction (PCR) and next-generation sequencing (NGS), which can detect specific genetic abnormalities associated with T-ALL.

The purpose of MRD analysis is to assess the effectiveness of treatment and to monitor disease progression or relapse. By detecting and quantifying minimal residual disease, doctors can determine if additional treatment is needed or if the disease is in remission.

MRD analysis is typically performed at multiple time points during and after treatment, such as after induction therapy, consolidation therapy, and maintenance therapy. The results are reported as a percentage of cancer cells detected in relation to the total number of cells analyzed.

Overall, MRD analysis for T-ALL plays a crucial role in guiding treatment decisions and monitoring the response to therapy. It helps healthcare providers determine the appropriate course of action to achieve the best possible outcomes for patients with T-ALL.

SKU: TEST-4770